希腊产KPC-2、SHV-106、CTX-M-15和VEB-1的高风险耐碳青霉烯肺炎克雷伯菌ST307克隆报告

IF 4.3 2区医学 Q1 INFECTIOUS DISEASES

Antibiotics-Basel Pub Date : 2025-05-31 DOI:10.3390/antibiotics14060567

Maria Chatzidimitriou, Pandora Tsolakidou, Maria Anna Kyriazidi, Sotiris Varlamis, Ilias S Frydas, Maria Mavridou, Stella Mitka

{"title":"希腊产KPC-2、SHV-106、CTX-M-15和VEB-1的高风险耐碳青霉烯肺炎克雷伯菌ST307克隆报告","authors":"Maria Chatzidimitriou, Pandora Tsolakidou, Maria Anna Kyriazidi, Sotiris Varlamis, Ilias S Frydas, Maria Mavridou, Stella Mitka","doi":"10.3390/antibiotics14060567","DOIUrl":null,"url":null,"abstract":"Background/objectives: Klebsiella pneumoniae ST307 is emerging as a significant global high-risk antimicrobial-resistant (AMR) clone with a notable capacity to acquire and disseminate resistance genes. However, there is limited research on the pathogenicity, virulence, and adaptation of ST307 strains and on the clinical characteristics of infected patients.Methods: In this study, a carbapenem-resistant K. pneumoniae (CRKP) ST307 strain named U989 was isolated from a urine culture of a hospitalized patient in Volos, Greece, in July 2024. Whole-genome sequencing was performed to identify resistance genes to β-lactams blaKPC-2, blaCTX-M-15, blaTEM-1B, blaOXA-1, blaOXA-10, blaSHV-106, and blaVEB-1 and resistance genes to other antibiotics.Results: A genomic analysis also revealed the presence of virulence factors such as iutA, clpK1, fyuA, fimH, mrkA, Irp2, and TraT and an IncFiB(pQil)/IncFII(K) replicon, which harbors the blaKPC-2 gene. Additionally, the transposable element Tn4401 was identified as a key vehicle for the mobilization of the blaKPC-2 resistance gene. Finally, this is the report of a high-risk CRKP ST307 clone expressing KPC-2, SHV-106, CTX-M-15, and VEB-1 bla genes in Greece.Conclusions: The coexistence of these resistance genes in addition to aminoglycoside, quinolone, and other resistance genes results in difficult-to-treat infections caused by respective carrier strains, often requiring the use of last-resort antibiotics and contributing to the global challenge of antimicrobial resistance.","PeriodicalId":54246,"journal":{"name":"Antibiotics-Basel","volume":"14 6","pages":""},"PeriodicalIF":4.3000,"publicationDate":"2025-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12189958/pdf/","citationCount":"0","resultStr":"{\"title\":\"Report of High-Risk Carbapenem-Resistant K. pneumoniae ST307 Clone Producing KPC-2, SHV-106, CTX-M-15, and VEB-1 in Greece.\",\"authors\":\"Maria Chatzidimitriou, Pandora Tsolakidou, Maria Anna Kyriazidi, Sotiris Varlamis, Ilias S Frydas, Maria Mavridou, Stella Mitka\",\"doi\":\"10.3390/antibiotics14060567\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background/objectives: Klebsiella pneumoniae ST307 is emerging as a significant global high-risk antimicrobial-resistant (AMR) clone with a notable capacity to acquire and disseminate resistance genes. However, there is limited research on the pathogenicity, virulence, and adaptation of ST307 strains and on the clinical characteristics of infected patients.Methods: In this study, a carbapenem-resistant K. pneumoniae (CRKP) ST307 strain named U989 was isolated from a urine culture of a hospitalized patient in Volos, Greece, in July 2024. Whole-genome sequencing was performed to identify resistance genes to β-lactams blaKPC-2, blaCTX-M-15, blaTEM-1B, blaOXA-1, blaOXA-10, blaSHV-106, and blaVEB-1 and resistance genes to other antibiotics.Results: A genomic analysis also revealed the presence of virulence factors such as iutA, clpK1, fyuA, fimH, mrkA, Irp2, and TraT and an IncFiB(pQil)/IncFII(K) replicon, which harbors the blaKPC-2 gene. Additionally, the transposable element Tn4401 was identified as a key vehicle for the mobilization of the blaKPC-2 resistance gene. Finally, this is the report of a high-risk CRKP ST307 clone expressing KPC-2, SHV-106, CTX-M-15, and VEB-1 bla genes in Greece.Conclusions: The coexistence of these resistance genes in addition to aminoglycoside, quinolone, and other resistance genes results in difficult-to-treat infections caused by respective carrier strains, often requiring the use of last-resort antibiotics and contributing to the global challenge of antimicrobial resistance.\",\"PeriodicalId\":54246,\"journal\":{\"name\":\"Antibiotics-Basel\",\"volume\":\"14 6\",\"pages\":\"\"},\"PeriodicalIF\":4.3000,\"publicationDate\":\"2025-05-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12189958/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Antibiotics-Basel\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3390/antibiotics14060567\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Antibiotics-Basel","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/antibiotics14060567","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

摘要

背景/目的：肺炎克雷伯菌ST307正在成为一种重要的全球高风险抗微生物药物耐药性（AMR）克隆，具有显著的获得和传播耐药基因的能力。然而，对ST307菌株的致病性、毒力、适应性以及感染患者的临床特征研究有限。方法：在本研究中，从2024年7月希腊Volos住院患者的尿液培养中分离出一株耐碳青霉烯类肺炎克雷伯菌（CRKP） ST307菌株，命名为U989。全基因组测序鉴定β-内酰胺类药物blaKPC-2、blaCTX-M-15、blaTEM-1B、blaOXA-1、blaOXA-10、blaSHV-106、blaVEB-1耐药基因及其他抗生素耐药基因。结果：基因组分析还揭示了毒力因子如iutA、clpK1、fyuA、fimH、mrkA、Irp2和TraT的存在，以及包含blaKPC-2基因的IncFiB(pQil)/IncFII(K)复制子的存在。此外，转座元件Tn4401被确定为调动blaKPC-2抗性基因的关键载体。最后，这是在希腊报道的表达KPC-2、SHV-106、CTX-M-15和VEB-1 bla基因的高危CRKP ST307克隆。结论：这些耐药基因与氨基糖苷类、喹诺酮类和其他耐药基因共存，导致由各自的载体菌株引起的难以治疗的感染，往往需要使用最后手段的抗生素，从而加剧了全球抗微生物药物耐药性的挑战。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Report of High-Risk Carbapenem-Resistant K. pneumoniae ST307 Clone Producing KPC-2, SHV-106, CTX-M-15, and VEB-1 in Greece.

Background/objectives: Klebsiella pneumoniae ST307 is emerging as a significant global high-risk antimicrobial-resistant (AMR) clone with a notable capacity to acquire and disseminate resistance genes. However, there is limited research on the pathogenicity, virulence, and adaptation of ST307 strains and on the clinical characteristics of infected patients.

Methods: In this study, a carbapenem-resistant K. pneumoniae (CRKP) ST307 strain named U989 was isolated from a urine culture of a hospitalized patient in Volos, Greece, in July 2024. Whole-genome sequencing was performed to identify resistance genes to β-lactams bla_KPC-2, bla_CTX-M-15, bla_TEM-1B, bla_OXA-1, bla_OXA-10, bla_SHV-106, and bla_VEB-1 and resistance genes to other antibiotics.

Results: A genomic analysis also revealed the presence of virulence factors such as iutA, clpK1, fyuA, fimH, mrkA, Irp2, and TraT and an IncFiB(pQil)/IncFII(K) replicon, which harbors the bla_KPC-2 gene. Additionally, the transposable element Tn4401 was identified as a key vehicle for the mobilization of the bla_KPC-2 resistance gene. Finally, this is the report of a high-risk CRKP ST307 clone expressing KPC-2, SHV-106, CTX-M-15, and VEB-1 bla genes in Greece.

Conclusions: The coexistence of these resistance genes in addition to aminoglycoside, quinolone, and other resistance genes results in difficult-to-treat infections caused by respective carrier strains, often requiring the use of last-resort antibiotics and contributing to the global challenge of antimicrobial resistance.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Antibiotics-Basel Pharmacology, Toxicology and Pharmaceutics-General Pharmacology, Toxicology and Pharmaceutics

CiteScore

7.30

自引率

14.60%

发文量

1547

审稿时长

11 weeks

期刊介绍： Antibiotics (ISSN 2079-6382) is an open access, peer reviewed journal on all aspects of antibiotics. Antibiotics is a multi-disciplinary journal encompassing the general fields of biochemistry, chemistry, genetics, microbiology and pharmacology. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. Therefore, there is no restriction on the length of papers.